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Biodegradable ion-exchange microspheres, prepared from a prefabricated conjugate of albumin and 
heparin were investigated as carriers for adriamycin. The ion-exchange microspheres could be loaded 
with adriamycin giving payloads up to 33% w/w, depending on the heparin content of the conjugate. 
In vitro adriamycin release depended on the ionic strength of the release medium. In ion containing 
media, for instance saline, 90% of the drug was released within 45 min, whereas in non-ionic media, 
such as distilled water, only 30% was released. Drug release profiles could be modelled by combining 
ion-exchange kinetics and diffusion controlled drug release models. 
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Introduction 
Cytostatic agents are widely used for the treat- 
ment of cancer. In general these drugs have nar- 
row therapeutic windows. Due to the high sys- 
temic levels of the drug needed to achieve 
sufficiently high drug levels at the tumour site, 
severe side effects can occur. Adriamycin 
(ADR), for instance, is known to cause car- 
diomyopathy [ 1,2]. A reduction of the side ef- 
fects can be achieved by targeting the drug to the 
site of the tumour, thus reducing systemic drug 
levels and confining the cytotoxicity of the drug 
to the tumour. 
Microspheres are suitable carriers to be used 
for drug targeting [ 3,4]. Administration of drug- 
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loaded particles of the requisite size ( 15-60 pm), 
may cause tumour infarction by occlusion or in- 
duce transient ischemia within the tumour vas- 
culature, whereupon the entrapped drug can be 
released locally. Moreover, tissue permeability is 
increased due to anoxia, allowing the drug to 
permeate more easily into the tissue [ 5 1. 
Albumin microspheres ( AMS ) have received 
much attention as possible devices for chem- 
oembolization [ 6,7]. However, the use of AMS 
for the release of ADR has some drawbacks. The 
preparation methods afford only low payloads 
( 1- 10%). Furthermore ADR may react with the 
crosslinking agent during the stabilization pro- 
cess, or may decompose when the microspheres 
are stabilized at high temperatures [ 8,9]. AMS 
are somewhat hydrophobic and surfactants are 
needed to resuspend them in aqueous solutions. 
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Another problem in the use of ADR-loaded AMS 
is the large burst effect usually observed. In any 
aqueous medium 80-90% of the drug is released 
within 30 min. As a result it is hard to handle the 
formulation in a clinical situation. 
Previously it has been shown that some of these 
problems do not occur if microspheres are highly 
negatively charged and thus have ion-exchange 
properties [lo]. With AMS, this has been 
achieved by the incorporation of carboxylic acid 
groups containing polyelectrolytes like poly (cy- 
L-glutamic acid) [ 11) or poly (&aspartic acid) 
[ 12 ] into the microspheres. More recently neg- 
atively charged, biodegradable vesicles, have 
been prepared by the incorporation of heparin in 
albumin microspheres [ 13,141. Heparin is a 
negatively charged mucopolysaccharide. In ad- 
dition to weak acidic carboxylic acid groups, 
heparin also contains strong acidic sulphate and 
sulphamate groups. Heparin and ADR are known 
to form ionic complexes. Menozzi and Arca- 
mone [ 151 studied the in vitro interaction of 
heparin and ADR, whereas Cofrancesco et al. 
[ 16 ] reported that ADR inhibits the anticoagu- 
lant activity of heparin in vivo. 
Albumin-heparin conjugate microspheres are 
prepared according to well documented emul- 
sion stabilization techniques used in AMS prep- 
aration [ 61. The conjugate used in the micros- 
phere preparation is synthesized as described by 
Hennink et al. [ 17 1. Details on the manufactur- 
ing of the conjugates and the microspheres are 
described elsewhere [ 18 1. Due to the ion-ex- 
change properties of the carrier, ADR loading of 
the microspheres can be carried out after micros- 
phere preparation by incubating the micro- 
spheres in an ADR solution [ 131. It has also been 
demonstrated that AHCMS can be loaded with 
other drugs of higher molecular weight by a 
swelling-deswelling process [ 19 1. 
In this paper the ADR loading and in vitro re- 
lease characteristics of AHCMS are described. 
The released material was characterized by 
HPLC and the activity was tested using a B16 
colony formation assay. Furthermore the drug 
release profile was modelled using ion-exchange 
and diffusion controlled release kinetics. 
Materials and methods 
Materials 
Highly refined olive oil and porcine serum al- 
bumin (fraction V) were obtained from Sigma 
Chemical Company, St. Louis, USA. Glutaral- 
dehyde (25% aqueous solution), obtained from 
Merck, Darmstadt, Germany, was purified by 
distillation [ 201 and adjusted to 2.5, 5 and 25% 
w/v aqueous solutions prior to use. Phosphate- 
buffered saline (PBS) was obtained from NPBI, 
Emmer Compascuum, The Netherlands. Adria- 
mycin was a kind gift from Farmitalia Carlo 
Erba, Milan, Italy. A batch of 0.26 mg of 14C- 
adriamycin with a specific activity of 95 @Zi/mg, 
was obtained from Amersham, UK (batch no. 
14). It was mixed with 100 mg of unlabelled 
adriamycin. Soluene@ and the scintillation fluids 
Optifluor@, UltimaGold@ and Dimilume-30@ 
were obtained from Packard Instrument B.V., 
Chemical Operations, Groningen, The Nether- 
lands. All other reagents were obtained, in the 
highest possible grade, from Merck, Darmstadt, 
Germany. 
Albumin-heparin conjugates 
The preparation and characterization of albu- 
min-heparin conjugates was carried out as de- 
scribed by Cremers et al. [ 18 1. Two different 
conjugates were prepared from human serum al- 
bumin and heparin. An unfractionated conju- 
gate with a heparin content of 10.7 20.9% w/w 
( AHC) . And a high-affinity conjugate (ha-AHC ) 
prepared by fractionation of an unfractionated 
conjugate by ion-exchange chromatography us- 
ing a DEAE-sepharose column. The heparin 
content of the ha-AHC was 10.2 ? 1.2%. Further- 
more albumin-heparin conjugates, prepared from 
porcine albumin with heparin contents of 5.9% 
(p-AHCl), 16.0% (p-AHC2) and 21.5% (p- 
AHC3) as indicated by the manufacturer, were 
obtained from Holland Biomaterials Group 
(HBG), Enschede, The Netherlands. 
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TABLE 1 
Microspheres used for drug loading and release experiments 
Code” Glutaraldehyde Reduction 
concentration with 
(O/O) NaBH,CN 
Quenching 
with 
glycine 
Heparin 
content 
(%) 
AHCMSlO 1.0 - 10.7 
AHCMSl OQb 1.0 - + 10.7 
AHCMSl ORQb 1.0 + + 10.7 
AHCMSOS 0.5 - - 10.7 
AHCMSSO 5.0 - 10.7 
ha-AHCMS 10’ 1.0 - - 10.2 
PSAMSOS 0.5 - 0.0 
p-AHCl MSOSd 0.5 - 5.9 
p-AHC2MSOSd 0.5 - 16.0 
p-AHC3MSOSd 0.5 - 21.5 
aNumbers refer to crosslink density. 
“Capitals refer to extra process conditoin: R, reduction; Q, quenching. 
‘Prepared from conjugate with high-affinity towards DEAE-sepharose ion-exchange column (ha-AHC). 
dPrepared from porcine-albumin-heparin conjugates with varying heparin content: p-AHC 1, 5.9% heparin; p-AHCZ, 16% hepa- 
rin; p-AHC3,2 1.51 heparin. 
Microsphere preparation 
AHCMS were prepared according to methods 
developed for the preparation of AMS. In the 
microsphere preparation, the type of conjugate, 
i.e., heparin content, the crosslink density, re- 
duction with NaBH,CN and quenching with gly- 
tine were varied as described previously [ 18 1. 
In Table 1 the types of microspheres that have 
been used in drug loading and release experi- 
ments are listed. 
Adriamycin loading 
In a typical experiment, 10 mg of AHCMS was 
ultrasonically suspended in 1 ml of a 14C-adria- 
mycin solution (5 mg/ml water). This suspen- 
sion was gently rotated for 20 h at 4°C in the 
dark. The suspensions were then centrifuged, the 
loading solution was decanted and 1 ml of dis- 
tilled water was added to rinse the microspheres. 
After centrifugation, the washing solution was 
decanted again. This procedure was repeated 
three more times and was subsequently repeated 
four times with 1 ml of acetone to dehydrate the 
microspheres. The microspheres were left over- 
night at room temperature in the dark to evapo- 
rate the acetone, and subsequently dried in vacua 
for 3 h at room temperature. 
The loading kinetics were determined by mon- 
itoring the “C-adriamycin level in solutions dur- 
ing the drug loading. Samples were taken at var- 
ious time intervals. The maximal payload of the 
microspheres was determined using ADR load- 
ing solutions of increasing concentration (OS- 
10 mg/ml). ADR concentrations of loading and 
washing solutions were determined using HPLC. 
The HPLC system consisted of an ISCO HPLC- 
pump (model 2350), a Rheodyne injection valve 
(model 7 120) equipped with a fixed sample loop 
of 10 ~1 and a Chrompack C 18 microsphere (3 
pm) column ( 100x4.6 mm i.d.). ADR and 
ADR metabolites were detected using fluorime- 
try by a Perkin Elmer LS4 fluorescence spec- 
trometer at A,,,= 488 nm and A,,,= 588 nm. The 
mobile phase consisted of 73% v/v acetonitrile, 
27% v/v 0.05 M KH2P04, with the final pH ad- 
justed to 4.0 using orthophosphoric acid. A flow 
rate of 0.5 ml/min was applied. 
Adriamycin payload determination 
Depletion/recovery method 
The amount of ADR remaining in the loading 
solution and the ADR amounts in the washing 
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solutions were determined by 14C scintillation 
counting or by UV/Vis measurements. The pay- 
load was calculated from the adriamycin deple- 
tion of the loading solution and the adriamycin 
recovered from the washing and dehydration so- 
lutions. To have an indication of the stability of 
the ADR during these procedures, samples of the 
ADR in the washing and dehydration solutions 
were analysed by HPLC. 
Degradation method 
ADR-loaded microspheres (1 mg) were de- 
graded in 1 ml of Soluene@ for 65 h at 37°C and 
subsequently for 5 more hours at 65 “C. After 
cooling down to room temperature, 15 ml of 
Dimilume-30@ was added, and the mixture was 
vortexed. Radioactivity was determined using a 
scintillation counter (Hewlett Packard 1900 CA 
Tri-Carb Liquid Scintillation Analyzer, USA). 
As a control, 100 ~1 of a 14C-adriamycin solution 
(0.5 mg/ml) was pipetted into a vial containing 
approximately 1 mg of empty microspheres. The 
controls were further treated in the same way as 
the other vials. The payload of the microspheres 
was calculated using the specific activity that was 
determined from the controls. 
Adriamycin release 
Release experiments were carried out using a 
batch system. Microspheres ( t 1 mg, 5-35 pm) 
were weighed on an aluminium foil basket, which 
was put into a 20 ml polypropylene (PP) vial. 
Two hundred ~1 ethanol was added for better 
wetting and the microspheres were ultrasoni- 
cally resuspended. No drug release was observed 
during this procedure. At t = 0, 20 ml of release 
medium (PBS; human plasma, containing 0.02% 
sodium azide; 5% glucose solution; 5% albumin 
solution or distilled water) was added and the 
counting vials were put into a shaking bath at 
37 “C. The amplitude of the shaking was 2.5 cm 
and the frequency, approximately 2 Hz. At inter- 
vals, the PP vials were taken from the bath and 
shaken vigorously to homogenize the suspen- 
sion. A 0.5 ml sample was pipetted from the vial 
into a 1.5 ml Eppendorp cup. After centrifuga- 
tion for 5 s at 13000 rpm, two 200-~1 samples 
were taken from the supernatant, and trans- 
ferred into 6-ml counting vials. Scintillation me- 
dium (Optifluor@’ or UltimaGold@’ ) was added 
(4 ml) and the activity was determined. The re- 
lease profile was calculated from the activity of 
the samples. 
In order to mimic a clinical situation, release 
experiments ( n = 4) were carried out in which the 
microspheres ( +- 1 mg) were resuspended in 10 
ml of injection medium (5% w/v glucose solu- 
tion) at room temperature. The vials were left to 
stand in the dark. Every 15 min, they were shaken 
gently. After 1.5 h, 10 ml of a warm NaCl solu- 
tion was added. In this way the temperature of 
the medium was instantaneously increased to 
37’ C and the NaCl concentration was increased 
to a physiological level. The vials were placed in 
the shaking bath at 37°C. The release was mon- 
itored at 30-min time intervals as described 
previously. 
The influence of the ADR release on the swell- 
ing of the microspheres was investigated by 
measuring the release of ADR and the size dis- 
tribution of the AHCMS simultaneously. ADR- 
loaded AHCMSOS ( 16 mg ) were resuspended in 
150 ~1 ethanol. At t = 0 the suspension was added 
to 100 ml of PBS in the sample chamber of a 
Horiba LA 500 laser diffraction particle size dis- 
tribution analyser (Horiba, Kyoto, Japan). The 
suspension was continuously agitated and circu- 
lated through the measuring chamber. After var- 
ious time intervals, two 1 -ml samples were taken 
from the suspension and centrifuged at 13000 
rpm. From the supematant 0.9 ml was pipetted 
into a 1.5-ml EppendorfO cup and stored until 
ADR determination. This was done by UV/Vis 
spectroscopy. E494 was measured with an Uvi- 
kon 930 spectrophotometer (Kontron Instru- 
ments, Rotkreuz, Switzerland). The size distri- 
bution of the microspheres was also determined 
(between 0.5 and 200 pm, in 40 channels of 5 
pm each) at several time intervals. 
B16 colony formation assay of released adriamycin 
A standard suspension of 100 B 16 cells/3 ml 
was prepared in Dulbecco’s Modified Eagle’s 
Medium, containing 10% new-born calf serum 
(DMEM). Three ml of this suspension was 
added to wells of a six-well tissue culture plate. 
Cells were left to adhere for 24 h after which a 
15&ml ADR solution was added to a final 
concentration of 3, 1,0.3,0.1,0.03,0.0 1 or 0 pg/ 
ml ADR (n = 6 per concentration point, n= 10 
in controls). At the highest concentration ( 3 ,ug/ 
ml), 0.6 ml of medium was removed prior to the 
addition of the ADR solution. After 30 min ex- 
posure the ADR containing medium was re- 
moved, the wells were washed with PBS and fresh 
medium was added. The wells were kept for 5 
days at 37°C (5% COZ). The medium was then 
removed and the wells were washed with PBS. 
Cells and colonies were fixed using ethanol and 
stained with crystal violet. Colonies ( 2 50 cells) 
were counted using a light microscope. These ex- 
periments were carried out with four types of 
ADR: ADR as obtained from Farmitalia, i4C- 
ADR as used in the drug loading and release ex- 
periments, i4C-ADR as released from AHCMS 10 
and 14C-ADR as released from AHCMSIORQ 
(after 2 h release in PBS). The results from this 
experiment were analysed by probit-analysis. 
Results and Discussion 
Albumin-heparin conjugate microspheres were 
prepared from a prefabricated albumin-heparin 
conjugate by an emulsion-stabilization tech- 
nique. Since endogenous materials are used it is 
expected that the microspheres will be biocom- 
patible and biodegradable. Due to the introduc- 
tion of strong anionic groups by heparin incor- 
poration, the microspheres exert ion-exchange 
properties. The biodegradable ion-exchange 
microspheres were investigated as possible adri- 
amycin delivery devices to be used in intra-arte- 
rial chemo-embolization studies for targeting to 
the liver. 
Albumin-heparin conjugates were prepared as 
described previously [ 17,18 1. The ADR binding 
and release properties of the microspheres are 
predominantly determined by the ionic interac- 
tion between the drug and the heparin moieties 
of the conjugate. Increasing heparin contents will 
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thus result in higher payloads. DEAE ion-ex- 
change chromatography enables fractionation of 
the conjugate, yielding ha-AHC with a higher 
charge-density as compared to unfractionated 
AHC. This will also result in increased payloads. 
Microspheres with a diameter of 5-35 pm were 
prepared by the emulsion stabilization method. 
Crosslink density, reduction and quenching did 
not change the size distribution [ 18 1. Using the 
high-affinity conjugate, a more viscous aqueous 
solution was obtained (at the same conjugate 
concentration), resulting in larger microspheres 
with a larger size distribution. This is in accord- 
ance with the results obtained with AMS. The di- 
ameter of AMS increases with increasing viscos- 
ity of the aqueous phase as well as with decreasing 
stirring speed, decreasing viscosity of the organic 
phase and increasing amount of aqueous phase 
16,181. 
Compared with AMS, the AHCMS are more 
hydrophilic and relatively easy to resuspend in 
aqueous medium. This enables resuspension of 
AHCMS in the ADR containing loading solu- 
tion. Due to the negatively charged heparin 
moieties in the microspheres, the loading of the 
positively charged ADR is a fast and efficient 
process as can be seen in Fig. 1. If an ADR/ 
AHCMS ratio of l/2 (w/w) was used, drug 
loading was complete after 2-3 h and approxi- __ 
mately 90% of the drug initially present in the 
loo+ 
.5 0 
z 20 o 8 
: 00 oe c! 
0 12 3 4 15 30 45 60 75 
time [h] 
Fig. 1. Relative amount of ADR in the loading solution dur- 
ing ADR loading of 10 mg of AHCMSOS using 1 ml of an 
ADR solution of 5 mg/ml; ADR/AHCMS ratio=0.5 mg/mg 
(n=4). 
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loading solution was entrapped in the spheres as a function of the concentration of the 
microspheres. loading solution is given. 
The binding capacity of ADR to AHCMS was 
limited. At higher concentrations the ADR bind- 
ing became saturated. Increasing the concentra- 
tion in the loading solution to an ADR/AHCMS 
ratio of 1 / 1 (w/w) gave only a small increase in 
payload. This is demonstrated in Figs. 2 and 3 in 
which the maximum ADR payload of the micro- 
Fig. 2 also shows that the efficiency of the ADR 
loading is influenced by the ADR/AHCMS ratio 
used in the loading procedure. The loading effi- 
ciency, expressed as the relative ADR depletion 
from the loading solution, was almost 100% up 
to the level at which the maximal loading capac- 
ity was reached. This also indicates that under 
these circumstances, no unbound ADR is pres- 
ent. Unbound ADR, removed during the wash- 
ing and dehydration procedure would give a 
lower efficiency. 
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Fig. 2. Influence of the ADR/AHCMS ratio on the payload 
( 0 ) and the loading efficiency ( 0 ) , after 24 h of drug load- 
ing (n = 2). AHCMS ( 10 mg ) were suspended in 1 ml of ADR 
solution (0.5-lOmg/ml). The payloads were determined us- 
ing the depletion method. 
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Fig. 3. Influence of the ADR/p-AHCMS ratio on the payload 
after 24 h of drug loading (n=4). p-AHCMS (5 mg) were 
suspended in 1 ml of ADR solution (0.8-8.0 mg/ml). 0, 
PSAMS (0% heparin); 0, p-AHCIMS (5.9% heparin); n , 
p-AHC2MS ( 16.0% heparin); A, p-AHC3MS (2 1.5% hepa- 
tin). The payloads were determined using the depletion 
method. 
The payloads obtained with the different types 
TABLE 2 
Adramycin payloads of AFCMS 
MS-type” Payload 
Depletion 14Cb Degradation 
,4(-J 
AHCMSIO 
AHCMSIOQ 
AHCMSlORQ 
AHCMSSO 
ha-AHCMS 10 
22.8k2.2 25.6? 1.3 
24.4f 1.6 29.0+ 1.8 
22.6kO.5 26.5f 1.0 
29.5+ 1.0 21.9? 1.7 
32.2k0.8 31.9k2.4 
“Microsphere code are explained in Table 1. 
‘Calculated from the results obtained by the ADR depletion/ 
recovery method ( n = 4 ) 
“Calculated from the results obtained by the degradation 
method (n=2). 
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Fig. 4. Maximal ADR payloads as a function of the heparin 
contents of albumin-heparin conjugate microspheres: 0, MS 
prepared from PSA or p-AHC; 0, AHCMSOS. 
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of microspheres are given in Table 2. Figs. 3 and 
4 show the influence of the heparin content of 
the microspheres on the drug loading capacity of 
p-AHCMS. With increasing heparin content, 
higher payloads can be reached. Fig. 4 also shows 
that p-AMS can bind some ADR, although the 
payload is less than that of p-AHCMS. 
From Table 2 and Fig. 4 it can be concluded 
that the charge density of the heparin and the 
heparin content are the most important param- 
eters determining the payload. Previously, Men- 
ozzi and Arcamone [ 15 ] have determined the 
ADR-binding capacity of heparin. They found 
that 3.3 mol of ADR could be bound per mol of 
hexosamine residues of heparin. It was deter- 
mined that, in solution, the unfractionated al- 
bumin-heparin conjugate had an ADR binding 
capacity of 3.2 mol of ADR/mol of hexosamine 
residues (data not shown). Therefore the ADR- 
heparin binding appears not to be influenced by 
the covalent coupling of albumin and heparin. 
The ADR-heparin binding experiments with 
solutions suggest hat several types of drug bind- 
ing occur. Next to an initial electrostatic binding 
between the basic group of the aminosugar 
moiety of the drug and the polyanionic macrom- 
olecule, the drug binding may be enhanced by 
self-association of ADR due to hydrophobic in- 
teractions between ADR molecules [ 15 1. For- 
mation of ADR aggregates in concentrated solu- 
tions is a well know phenomenon, which was 
described previously [ 2 I]. 
As pointed out before, fractionation of the 
conjugate based on ionic interaction with DEAE 
sepharose, yields a conjugate which will also show 
more affinity towards ADR as compared to un- 
fractionated AHC. Accordingly the ADR pay- 
loads of microspheres prepared from the high-af- 
finity conjugate (ha-AHCMS 10) were higher 
than that of microspheres prepared from unfrac- 
tionated conjugate (32% instead of approxi- 
mately 27%, Table 2). The importance of the 
heparin and the heparin-ADR interaction is also 
demonstrated by the increased ADR binding ca- 
pacity with increasing heparin content (Fig. 3 ). 
Furthermore, Table 2 shows that the concentra- 
tion of the crosslinking agent, quenching and re- 
duction had virtually no influence on the pay- 
load. From these results it can be concluded that 
the charge density of the matrix material is the 
most important factor determining the final pay- 
load. The drug loading process is a very attrac- 
tive one since it allows effective drug loading with 
little or no drug loss during the procedure. 
The payloads determined by the depletion/re- 
covery method or by the degradation method are 
in good agreement. This shows that the more 
convenient, widely used depletion/recovery 
method is reliable. A disadvantage of the two 
methods is that the quality of the incorporated 
adriamycin cannot be monitored. However, 
HPLC analysis of the material recovered in the 
washing steps (data not shown) showed that no 
degradation of the adriamycin took place during 
drug loading and washing steps. 
ADR release from AHCMS is controlled by the 
ionic strength of the medium, as is shown in Fig. 
5. The release in ion-containing media such as 
phosphate-buffered saline and human plasma 
was very fast. Almost all of the drug was released 
within 2 h. In non-ionic media, however, only 
30% of the drug was released. The ion controlled 
release provides a method to prepare an ADR- 
AHCMS suspension containing little or no free 
drug. This is demonstrated in Fig. 6. Maximally 
30% of the drug is released prior to ‘injection’. 
0 60 120 160 240 300 360 1480 
time (min] 
Fig. 5. Cumulative ADR release from AHCMSOS in several 
release media at 37°C. 0, phosphate-buffered saline; 0, hu- 
man plasma containing 0.02% sodium azide; A, 5O/o w/v al- 
bumin solution; Cl, distilled water; n , 5% w/v glucose solu- 
tion. Error bars indicate SD (n= 4). 
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Fig. 6. Cumulative ADR release from AHCMSlO in 5% w/v 
glucose solution at 20°C. At t =90 min (arrow), warm saline 
was added to increase the NaCl concentration of the release 
medium to a physiological evel and the temperature to 37’ C 
(n=4). 
Upon increasing the salt concentration up to 
physiological levels by addition of a salt solu- 
tion, thus imitating injection, the remaining ADR 
was released immediately. Another important 
feature is that ADR remaining in the AHCMS 
after the initial release is not released in fresh 
glucose solution, indicating that the ADR re- 
leased prior to the injection can be removed us- 
ing a simple washing step with non-ionic me- 
dium. This would be impossible with AMS, 
releasing the ADR in any aqueous solution, re- 
gardless of the ionic strength. Comparing 
AHCMS and AMS the major improvement of 
AHCMS is the obtained control over the onset 
of the drug release. 
The drug release in non-ionic medium (30%) 
was unexpected since the ADR ought to be bound 
ionically to the matrix. Moreover, no drug was 
released in water during the washing steps in the 
drug loading procedure. It was already men- 
tioned, however, that the electrostatic interac- 
tion of the ADR and the matrix is not the only 
mode of binding in this system. Apart from this 
type of binding, a substantial amount of ADR will 
be bound by self-association of ADR. It is sug- 
gested that due to the dehydration steps with 
acetone during the drug loading procedure, some 
of the hydrophobically bound ADR is detached 
from the ionically bound ADR. Previously, it has 
been shown that the dimerization equilibrium of 
anthracyclines such as adriamycin and dauno- 
mycin is shifted towards free drug in the pres- 
ence of organic solvents [ 22,23 1. This drug re- 
mains trapped in the dehydrated microsphere as 
unbound drug. Upon swelling in water, this drug 
is released, regardless of the ionic strength of the 
medium. 
Fig. 7 shows the ADR release profiles from 
several types of AHCMS. As can be seen from 
this figure, the ADR release profile was not in- 
fluenced by the quenching and reduction steps, 
nor by fractionation of the conjugate. All micro- 
spheres crosslinked with 1 .O% glutaraldehyde re- 
leased the drug within 45 min. There was an in- 
fluence of crosslink density, i.e., the drug release 
from microspheres crosslinked with 5.0% glutar- 
aldehyde (AHCMSSO) was slower. The ha- 
AHCMSSO seemed to release the drug even 
slower. The ha-AHCMSSO, however, have been 
prepared under different emulsification condi- 
tions, resulting in larger microspheres ( 12-80 pm 
instead of 5-35 pm). 
Fig. 7 also shows that not all of the drug was 
released from the microspheres. In the best case 
(AHCMSIORQ) 90% was released, most other 
types of microspheres released approximately 
80°V0 of the ADR. If this is due to covalent bind- 
ing of ADR to the unreacted aldehyde groups of 
the glutaraldehyde, quenching should result in 
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Fig. 7. Cumulative ADR release from several types of AHCMS 
in phosphate buffered saline at 37°C. A, AHCMSIO; 0, 
AHCMSlOQ; q , AHCMSlORQ; 0, AHCMSSO; A, ha- 
AHCMSlO; n , ha-AHCMSSO (n=4). 
more complete drug release. AHCMSlOQ have 
been quenched by addition of glycine during the 
microsphere preparation and the maximal re- 
lease of these microspheres was not different 
from that of AHCMSSO or ha-AHCMSIO. 
Quenching with glycine in the presence of a re- 
ducing agent ( AHCMS 1 ORQ ), however, did re- 
sult in relatively higher drug releases. This indi- 
cates that adequate quenching may only be 
achieved if a reducing agent is present. It also in- 
dicates that some of the drug remaining in the 
non-quenched microspheres after drug release, 
may be covalently bound to the matrix. Since 
ADR release from AHCMSlORQ is only 90%, 
covalent coupling of ADR to the albumin-hepa- 
rin conjugate matrix does not account for all of 
the drug remaining in the microspheres. An ex- 
planation for the drug remaining in the micro- 
spheres is the stabilization of electrostatically 
bound ADR by hydrophobic interactions with 
other ADR molecules, which was already men- 
tioned before. Menozzi and Arcamone [ 151 
found that in solution, only 50% of the ADR 
could be displaced from the heparin by Na+ at 
physiological concentrations. ADR-conjugate 
binding studies carried out with solutions showed 
that, in phophate buffered saline, only 80% of the 
drug was displaced from the conjugate (data not 
shown). Based on these results it is likely that 
some of the ADR aggregates, electrostatically 
bound to the matrix cannot be detached by 
counterions in the release medium. 
From the HPLC analysis of the released ma- 
terial it was concluded that after 2 h release at 
37 “C no degradation products of ADR were 
formed (data not shown). The dose/response 
curves of the different ADR samples, as calcu- 
lated from the B16 CFA, are shown in Fig. 8. 
There were no significant differences between the 
LDSo values of the four types of ADR used in the 
tests, as determined by probit-analysis. These re- 
sults prove that during drug loading and in vitro 
release procedures no degradation of the ADR 
occured. The released material was still active 
ADR. 
80 
adriamycin &g/ml] 
Fig. 8. Dose-response curves for various ADR samples as de- 
termined by a B 16 colony formation assay and calculated us- 
ing probit analysis. -, ADR; -----, “‘C-ADR; -.-.-.-.-, “‘C- 
ADR released from AHCMS 10; - - - - -, “‘C-ADR released 
from AHCMSl ORQ. 
Modelling of adriamycin release 
Considering the ion-exchange properties of the 
AHCMS several steps in the adriamycin release 
process can be distinguished: 
l swelling of the microspheres in the release 
medium; 
l in-diffusion of the counter ions; 
l actual ion-exchange of counter ions and drug; 
l out-diffusion of the drug. 
As was shown before, the swelling behaviour of 
the AHCMS is sensitive to the ionic strength of 
the medium, i.e., to the presence of ions [ 181. 
Possibly, the swelling will change during the drug 
release, i.e., during the exchange of larger hydro- 
phobic drug molecules with small ions. Fig. 9, 
however, shows that the swelling is very fast as 
compared to the drug release. In this figure the 
D &O% 25%7 (median) and &%, which are the di- 
ameters where the given percentage of particles 
is smaller than that size, as well as the ADR re- 
lease profile are presented. The figure also shows 
that the size distribution of the AHCMS was 
constant throughout the ADR release. 
Assuming that the actual ion-exchange is very 
fast as compared to the diffusion processes, the 
drug release rate is mainly controlled by the in- 
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Fig. 9. Size distribution of AHCMSOS during ADR release in 
phosphate buffered saline at 25’ C. o ‘. ., ADR release ex- 
pressed as the E 494 of the release medium; -, size distribu- 
tion as indicated by Dzss, Dso% and D75sr which are the di- 
ameters where the given percentage of particles is smaller than 
that size. 
diffusion of the counter ions and the out-diffu- 
sion of the drug. 
Ion-exchange kinetics have been described ex- 
tensively by Hellferich [ 241. Briefly, the total 
counter ion concentration (ions and drug) must 
remain constant (in equivalents) and equal to 
the amount of charged groups in the matrix. This 
implies that the fluxes (in equivalents) of the 
counter ions (in-diffusion) and the drug (out- 
diffusion) should be equal. So, instead of two in- 
dependent diffusion processes, there is a rigid 
coupling between the two fluxes and the kinetic 
behaviour can be calculated from only one dif- 
fusion equation. 
JA = - Di,,gradCA 
where the interdiffusion coefficient is: 
(1) 
Dint =DADB 2 
ZiCA +z;ca 
zACADA +z;CBD, 
Hellferich [ 241 has given a detailed description 
of these equations. 
Essentially, the release behaviour can be de- 
scribed by a diffusion equation in which the in- 
terdiffusion coefficient (Oi,,) is determined by 
the relative concentrations and the diffusion 
coefficients of the drug and the counter ion (resp. 
C,, C,, D, and &). This interdiffusion coefli- 
cient is not constant but is predominantly con- 
trolled by the ion which is in the minority. From 
Eq. 2 it can be seen that Dint = DA if C, -=K C,. In 
the case of ion-exchange in the microspheres, it 
may be assumed that after swelling, the drug 
concentration is much lower than the concentra- 
tion of the counter ion. So the interdiffusion 
coefficient will almost equal the drug diffusion 
coefficient. Hence, the ADR release from 
AHCMS will be predominantly diffusion 
controlled. 
Mathematical descriptions of diffusion pro- 
cesses, suited to describe drug release from 
spherical monolithic devices were derived by 
Crank [ 25 1. For the benefit of simplicity, early 
and late time approximations of these equations 
are generally used [ 26-28 1. The general equa- 
tion derived for spherical geometry by Crank 
[ 25 ] and the early and late time approximations 
are given in Eqs. 3, 4 and 5, respectively. 
Early time approximation: 
gL6 3 
m [ 1 
0.5 
-39 
Late time approximation: 
(3) 
(4) 
(5) 
From Eqs. 1 and 2 it was concluded that the ion- 
exchange kinetics could be described by a single 
diffusion equation in which the diffusion coeffi- 
cient was replaced by an interdiffusion coeffi- 
cient. This indicates that the adriamycin release 
from AHCMS could be described by Eqs. 4 and 
5, in which the diffusion coefficient D is the in- 
terdiffusion coefficient. In physiological salt so- 
lution, this interdiffusion coefficient will be con- 
stant and almost equal the diffusion coefficient 
of the adriamycin. 
Another problem is that the experimental re- 
lease data are data obtained from a population 
of microspheres of varying diameter. Donbrow 
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et al. [ 291 showed that in the case of microcap- 
sules, the zero-order single particle release pro- 
files may add up to first order population release 
kinetics. The effect of the size distribution of ion- 
exchange monolithic AHCMS on the release was 
investigated. For this purpose the size distribu- 
tion of the microspheres, presented in Fig. 10, 
was determined during the drug release. 
Fig. 11 shows the results of the ADR release 
from AHCMSOS in PBS at 37°C together with 
the release profile calculated by fitting Eq. 6 to 
these data, withA being the fraction of particles 
with a diameter of ri (as represented in Fig. 10). 
25 , 
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Fig. 10. Size distribution of AHCMSOS during ADR drug re- 
lease in PBS at 25 “C, determined in 40 channels of 5 pm each. 
Mean diameter, 30.8 pm; median diameter, 23.7 pm. 
0 60 120 160 240 
time [mitt] 
Fig. 11. Cumulative ADR release from AHCMSOS in PBS. 
0, experimental data, error bars indicate SD; -, release 
profile calculated with Eq. 6 to tit the experimental data us- 
ing the size distribution presented in Fig. 10; ----, release 
profile calculated with Eq. 6 withA= 1 and ri= 30.8 (mean 
diameter), using the Q,, from previous tit. 
From this fit the interdiffusion coefficient was 
determined to be 2.5E- 10 cm2 s-l. Fig. 11 also 
shows the release profile calculated with this in- 
terdiffusion coefficient and the mean diameter 
(30.8 pm) of the population. This mean-diame- 
ter profile was calculated using Eq. 6 with only 
one A and ri being 1 and 30.8 pm, respectively. 
Calculating the mean-diameter release profile 
using Eqs. 4 and 5 did not alter the result. 
(6) 
In Fig. 11 the experimental release data as well 
as the ‘population’-fit and the calculated ‘mean- 
diameter’ release profile are presented. It is ob- 
vious that, although the profiles are not exactly 
the same, the mean-diameter profile fits the ex- 
perimental data as well as the population release 
kinetics. This indicates that within the particle 
size distributions used in these release experi- 
ments, a ‘mean diameter’-tit procedure using Eqs. 
4 and 5, which is carried out more easily, is 
allowed. 
Fig. 12 shows the release profiles of adriamy- 
tin from AHCMS 10 in various media, fitted us- 
ing the early and late time approximations of the 
diffusion controlled release model (Eqs. 4 and 
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Fig. 12. ADR release from AHCMS 10 in several release me- 
dia at 37”C, fitted with early (-) and late (-----) time ap- 
proximations of diffusion controlled drug release kinetics 
from spherical monolithic devices (Eqs. 4 and 5). 0, phos- 
phate buffered saline; 0, human plasma containing 0.02% 
sodium azide; A, 5% w/v albumin solution; 0, distilled 
water; n , 5% w/v glucose solution. 
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5 ). The release profiles can be fitted very well 
with the early and late time approximations of 
the Fickian diffusion controlled release kinetics. 
In ionic medium such as physiological salt solu- 
tion and human plasma, the diffusion coefficient 
is the Dint of the ion-exchange kinetics. In non- 
ionic medium such as distilled water or 5% w/v 
glucose solution, the diffusion coefficient is sim- 
ply the diffusion coefficient of unbound ADR. 
In the case of 5% w/v albumin solutions, the 
situation is more complicated. In drug loading 
studies of AHCMS, Kwon et al. [ 191 showed that 
FITC-dextrans with an average weight molecu- 
lar weight of 17200 could only be loaded up to a 
payload of 0.5% after 50 h of incubation. There- 
fore it is not likely that albumin with a molecular 
weight of approximately 66000 will diffuse into 
the microspheres. Elemental analysis showed that 
the albumin contained 0.5% (w/w) of sodium. 
These sodium ions account for the ion-exchange 
that takes place during the ADR release in the 
albumin solution. The sodium, however, will also 
be bound to the albumin and the concentration 
in the microsphere will thus be relatively low and 
will change during drug release. As a result of this, 
the Dint will neither be constant nor almost equal 
to the diffusion coefficient of the ADR. Hence, 
straightforward fitting of the release profiles us- 
ing Eqs. 4 and 5 is not adequate anymore. 
Conclusions 
Albumin-heparin conjugate microspheres are 
biodegradable ion-exchange particles prepared 
from endogenous materials. The AHCMS could 
easily be loaded with the positively charged adri- 
amycin up to payloads of 1 O-34%, depending on 
the type of conjugate used. Drug release was ion- 
ically controlled and this enabled us to prepare 
injectable ADR-AHCMS suspensions in which 
the drug release was delayed until contact with 
body fluids. It was also shown that the drug re- 
lease can be described by combining well docu- 
mented ion-exchange kinetics and diffusion 
models. 
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